[go: up one dir, main page]

AR059349A1 - Sal especifica, forma hidratada y cristalina de un derivado de dihidropteridiona - Google Patents

Sal especifica, forma hidratada y cristalina de un derivado de dihidropteridiona

Info

Publication number
AR059349A1
AR059349A1 ARP070100503A ARP070100503A AR059349A1 AR 059349 A1 AR059349 A1 AR 059349A1 AR P070100503 A ARP070100503 A AR P070100503A AR P070100503 A ARP070100503 A AR P070100503A AR 059349 A1 AR059349 A1 AR 059349A1
Authority
AR
Argentina
Prior art keywords
derivative
dihydropteridion
hydrated
crystalline form
specific salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP070100503A
Other languages
English (en)
Inventor
Guenter Linz
Rolf Schmid
Matthias Grauert
Peter Sieger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica de C V SA filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of AR059349A1 publication Critical patent/AR059349A1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente se refiere a una sal específica de un derivado de dihidropteridiona, a saber, la sal de trihidrocloruro del compuesto N-[trans-4-[4-(ciclopropilmetil)-1-piperazinil]ciclohexil]-4-[[(7R)-7-etil-.5,6,7,8-tetrahidro-5-metil-8-(metiletil)-6- oxo-2-pteridinil]amino]-3-metoxi-benzamida, a su cristalizacion en la forma de un hidrato con agua, a un procedimiento para su fabricacion y su uso en una composicion farmacéutica.
ARP070100503A 2006-02-08 2007-02-07 Sal especifica, forma hidratada y cristalina de un derivado de dihidropteridiona Pending AR059349A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06101414 2006-02-08

Publications (1)

Publication Number Publication Date
AR059349A1 true AR059349A1 (es) 2008-03-26

Family

ID=38008126

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100503A Pending AR059349A1 (es) 2006-02-08 2007-02-07 Sal especifica, forma hidratada y cristalina de un derivado de dihidropteridiona

Country Status (22)

Country Link
US (3) US7439358B2 (es)
EP (2) EP1984367A1 (es)
JP (1) JP5134552B2 (es)
KR (2) KR101462879B1 (es)
CN (2) CN102093360B (es)
AR (1) AR059349A1 (es)
AU (1) AU2007213752B2 (es)
BR (1) BRPI0707604A8 (es)
CA (1) CA2635834C (es)
EA (2) EA018663B1 (es)
EC (1) ECSP088589A (es)
HK (2) HK1158628A1 (es)
IL (2) IL193217A (es)
NO (1) NO20082610L (es)
NZ (2) NZ570987A (es)
PE (2) PE20071248A1 (es)
SG (2) SG169397A1 (es)
TW (1) TW200738716A (es)
UA (2) UA101060C2 (es)
UY (1) UY30136A1 (es)
WO (1) WO2007090844A1 (es)
ZA (1) ZA200804587B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
ATE487720T1 (de) 2007-02-01 2010-11-15 Astrazeneca Ab 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EP3098223A1 (en) * 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
WO2009040556A1 (en) 2007-09-28 2009-04-02 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US8598172B2 (en) 2007-12-04 2013-12-03 Nerviano Medical Sciences S.R.L. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
EP2516441B1 (en) * 2009-12-23 2015-01-21 Elan Pharmaceuticals Inc. Pteridinones as inhibitors of polo-like kinase
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20140154304A1 (en) 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
EA201600133A1 (ru) * 2013-07-26 2016-07-29 Бёрингер Ингельхайм Интернациональ Гмбх Воласертиб в комбинации с децитабином для лечения острого миелоидного лейкоза и миелодиспластического синдрома
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
CN104003989B (zh) 2014-05-26 2015-11-11 苏州明锐医药科技有限公司 伏拉塞替及其中间体的制备方法
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN105646398B (zh) * 2014-12-05 2018-09-07 上海医药工业研究院 N-((1r,4r)-4-(4-(环丙基甲基)哌嗪-1-基)环己基)乙酰胺的制备方法
WO2016206619A1 (zh) * 2015-06-26 2016-12-29 苏州晶云药物科技有限公司 Volasertib及其三盐酸盐的新晶型
US20210038602A1 (en) 2018-01-25 2021-02-11 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia
CN119365489A (zh) 2022-04-08 2025-01-24 印希比生物科学有限公司 Dr5激动剂与plk1抑制剂或cdk抑制剂组合疗法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8303657A (nl) 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
JPH0276860A (ja) 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
FR2645152B1 (fr) * 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
CA2029651C (en) 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (es) * 1992-09-26 1996-04-21 Hoechst Ag
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9418499D0 (en) * 1994-09-14 1994-11-02 Ciba Geigy Ag Process for producing n-methylated organic pigments
CO4410191A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
WO1996036597A1 (en) * 1995-05-19 1996-11-21 Novartis Ag Process for the catalytic hydrogenation of aromatic nitro compounds
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
JP3887836B2 (ja) * 1995-12-21 2007-02-28 東ソー株式会社 Ｎ−メチルイミダゾール類の製造法
BR9711541A (pt) 1996-09-23 1999-08-24 Lilly Co Eli Dihidrato d de olanzapina
AU4924999A (en) * 1998-08-11 2000-03-06 Pfizer Products Inc. Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors
US7169778B2 (en) 1999-09-15 2007-01-30 Warner-Lambert Company Pteridinones as kinase inhibitors
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
NZ520962A (en) 2000-03-06 2003-09-26 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
DE10018783A1 (de) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US6960589B2 (en) * 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
IL160440A0 (en) 2001-09-04 2004-07-25 Boehringer Ingelheim Pharma Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1463493B1 (en) * 2001-12-14 2007-10-03 Laboratoires Serono SA Methods of inducing ovulation-using a non-polypeptide camp level modulator
EP1501794A1 (de) * 2002-05-03 2005-02-02 Schering Aktiengesellschaft Thiazolidinone und ihre verwendung als polo like kinase inhibitoren
FR2843114B1 (fr) 2002-08-01 2004-09-10 Poudres & Explosifs Ste Nale Procede de monomethylation d'heterocycles azotes
MXPA05001544A (es) 2002-08-08 2005-04-19 Smithkline Beecham Corp Compuestos de tiofeno.
US20040127504A1 (en) * 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ME00376B (me) 2003-02-26 2011-10-10 Boehringer Ingelheim Pharma DIHIDROPTERIDINONI, POSTUPAK ZA NJlHOVO PRIPREMANJE I NJlHOVA PRIMJENA KAO LIJEK
AU2004231464B2 (en) 2003-03-26 2010-08-05 Wyeth Immunogenic composition and methods
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
JP2007517828A (ja) 2004-01-17 2007-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 気道の疾患を治療するための置換プテリジンの使用
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de) * 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
CA2578560A1 (en) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for the production thereof, and use thereof as a medicament
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
CA2617589A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
JP2009515852A (ja) 2005-11-11 2009-04-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ／ｈｅｒ２インヒビターを含む癌の組み合わせ治療
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2007102767A1 (en) * 2006-03-07 2007-09-13 Astrazeneca Ab Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
EP3098223A1 (en) 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
JP4642085B2 (ja) 2008-01-17 2011-03-02 日本下水道事業団 予測健全度を利用した施設管理および更新計画システム
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2509592A1 (en) 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Bibw 2992 for use in the treatment of triple negative breast cancer
US20120329803A1 (en) 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors

Also Published As

Publication number Publication date
EA015389B1 (ru) 2011-08-30
NO20082610L (no) 2008-08-26
NZ606264A (en) 2014-08-29
TW200738716A (en) 2007-10-16
WO2007090844A1 (en) 2007-08-16
WO2007090844A8 (en) 2007-10-11
US8664222B2 (en) 2014-03-04
US20120214995A1 (en) 2012-08-23
EA200801769A1 (ru) 2009-02-27
EP2543669A3 (en) 2013-05-15
CA2635834A1 (en) 2007-08-16
US8188086B2 (en) 2012-05-29
EA201100638A1 (ru) 2011-10-31
CN101379064B (zh) 2012-01-25
JP5134552B2 (ja) 2013-01-30
EP1984367A1 (en) 2008-10-29
PE20071248A1 (es) 2008-01-15
UA101060C2 (ru) 2013-02-25
UY30136A1 (es) 2007-09-28
AU2007213752B2 (en) 2013-01-17
EA018663B1 (ru) 2013-09-30
IL193217A0 (en) 2009-02-11
US7439358B2 (en) 2008-10-21
NZ570987A (en) 2011-09-30
CN102093360A (zh) 2011-06-15
UA95625C2 (ru) 2011-08-25
BRPI0707604A2 (pt) 2011-05-10
US20070203146A1 (en) 2007-08-30
ZA200804587B (en) 2009-04-29
EP2543669A2 (en) 2013-01-09
KR20140082837A (ko) 2014-07-02
IL193217A (en) 2017-06-29
CN102093360B (zh) 2014-11-05
SG169397A1 (en) 2011-03-30
KR20080093068A (ko) 2008-10-17
ECSP088589A (es) 2008-07-30
BRPI0707604A8 (pt) 2017-12-26
CA2635834C (en) 2014-10-21
CN101379064A (zh) 2009-03-04
KR101445114B1 (ko) 2014-09-29
KR101462879B1 (ko) 2014-11-18
PE20110100A1 (es) 2011-02-18
HK1127772A1 (en) 2009-10-09
HK1158628A1 (en) 2012-07-20
SG10201404755SA (en) 2014-10-30
IL236736A0 (en) 2015-02-26
JP2009526017A (ja) 2009-07-16
AU2007213752A1 (en) 2007-08-16
US20090030004A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
AR059349A1 (es) Sal especifica, forma hidratada y cristalina de un derivado de dihidropteridiona
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
AR052404A1 (es) Hidratos y polimorfos de 4-(((7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil)amino)-3- metoxi-n-(1-metil-4-piperidinil)-benzamida, procedimiento para su preparacion y su uso como farmaco
WO2006077025A3 (en) Morpholines as 5ht2c agonists
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
AR061024A1 (es) Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
IL206450A (en) Use of a preparation that includes salt of o-acetylsalicylic acid and basic amino acid in the preparation of a drug for the prevention or treatment of viral infections
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
MX2010001742A (es) Nuevos derivados de piperazina-amida.
WO2009012375A3 (en) Squarate kinase inhibitors
MX2010005048A (es) Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465.
EA200801875A1 (ru) Антагонист cd 80
ITMI20051857A1 (it) Valvola per l'alimentazione in particolare di mezzi gassosi
WO2006051314A3 (en) Guanidine derivatives as inhibitors of ddah
AR065602A1 (es) Polimorfos de s , s dioxido del acido 7 - ( (3 - cloro-6 , 11 - dihidro-6-metildibenzo ( c , f ) (1 , 2 ) tiazepin- 11- il) amino ) heptanoico y metodos para su preparacion y uso
AR051213A1 (es) 1-(2-(4-bencil-4-hidroxi-piperidin-1-il)-etil)-3-(2-metil-quinolin-4-il)-urea como una sal sulfato cristalina
ITMI20051862A1 (it) Valvola per l'alimentazione in particolare di mezzi gassosi
ITMI20051859A1 (it) Valvola per l'alimentazione in particolare di mezzi gassosi
BRPI0416588A (pt) uso farmacêutico adicional
ITNA20060012U1 (it) Registro dei verbali di assemblea dei condomini
AR075295A1 (es) Hemisulfato monohidratado de tianeptina, composiciones farmaceuticas que lo contienen, metodo para prepararlo y uso del mismo para el tratamiento del asma y de la depresion.
TH68332A (th) การดัดแปลงผลึกของไตรอะซินิลอะมิโนสทิลบีน
FR2911947B1 (fr) Nouvelle fixation pour douille etanche d'ampoule.

Legal Events

Date Code Title Description
FC Refusal